Last updated: March 24, 2026
5-Amino-1MQ is NOT a peptide — it's a small molecule quinolinium compound that inhibits NNMT (nicotinamide N-methyltransferase). Research from UT Medical Branch shows it reduces fat cell size in mice. Zero human trials exist. Be honest: this is extremely early-stage.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a quinolinium-based small molecule inhibitor of NNMT. Unlike peptides, it's orally bioavailable.
5-Amino-1MQ is a quinolinium compound — not an amino acid chain like peptides. It can be taken orally unlike most peptides which require injection.
Targets nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in adipose tissue that consumes NAD+ precursors.
Unlike injectable peptides, 5-Amino-1MQ has demonstrated oral bioavailability in mouse studies — one reason for its popularity.
Discovered ~2019-2021. Only mouse data exists. No human safety or efficacy data. Not FDA approved for any indication.
Understanding why NNMT inhibition matters for metabolic health.
Nicotinamide (vitamin B3) is recycled into NAD+ through the salvage pathway. NNMT diverts nicotinamide away from NAD+ production.
NNMT uses S-adenosylmethionine (SAM) to methylate nicotinamide, producing 1-methylnicotinamide (1-MNA) — consuming methyl groups.
NNMT is highly expressed in fat cells. Obese individuals show elevated NNMT in adipose tissue, correlating with metabolic dysfunction.
Inhibiting NNMT may increase cellular energy expenditure in fat tissue and preserve NAD+ for mitochondrial function.
Key preclinical findings from the landmark NNMT inhibition study.
This study demonstrated that NNMT inhibition reduces fat mass and improves metabolic parameters in diet-induced obese mice.
5-Amino-1MQ has zero published human clinical trials. All evidence comes from mouse studies. This is among the earliest-stage compounds on our site. There is no established safe human dose, no long-term safety data, and no efficacy data in humans. Weight loss interest is entirely speculative and community-driven.
There is NO established human dose. These are extrapolations from animal studies.
Using standard mouse-to-human dose conversion (divide mouse mg/kg by 12.3), a 150 mg/kg mouse dose would equal approximately 12 mg for a 70kg human. However, this is a very rough estimate. Typical "research" references suggest 50-150mg orally — but this is entirely unvalidated.
There is essentially zero safety data in humans.
No human toxicity data exists. Long-term effects are completely unknown.
While oral bioavailability is convenient, it also means systemic exposure with unknown organ effects.
Research-grade compounds may contain impurities. No pharmaceutical-grade version exists.
No data on interactions with medications, supplements, or other compounds.
Despite community interest, there is zero evidence 5-Amino-1MQ produces weight loss in humans. GLP-1 agonists (semaglutide, tirzepatide) have far more evidence.
The risk-to-benefit ratio is unknown. Without human data, any use is essentially guesswork with potential for harm.
The only valid use case is in a research setting studying NNMT inhibition and metabolic disease.
If you're researching metabolic pathways or the NNMT mechanism, this page serves as an educational resource.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →This page is for educational purposes only. 5-Amino-1MQ is an extremely new compound with only mouse data. No human clinical trials exist. Not FDA approved. The compound has not been established as safe or effective for any use in humans. Always consult a healthcare provider before considering any research compound.